As we age, certain cells in the body stop dividing but do not die. These are known as senescent cells, often referred to as “zombie cells.” Instead of functioning normally, they accumulate in tissues and release inflammatory signals that contribute to aging and chronic disease. This process is one of the recognized hallmarks of aging.
Senolytics are a class of therapies designed to selectively remove these dysfunctional cells, allowing healthier cells to function more efficiently. By clearing senescent cells, researchers believe it may be possible to reduce chronic inflammation, improve tissue repair, and potentially delay the onset of age-related diseases.
Several compounds are currently being studied for their senolytic effects. Natural compounds such as fisetin and quercetin have shown promise in early research. Pharmaceutical combinations like dasatinib and quercetin have also been investigated for their ability to eliminate senescent cells in certain tissues. Other pathways being explored include drugs that influence the BCL-2 and mTOR pathways, both of which are involved in cell survival and aging mechanisms.
Early studies suggest that removing senescent cells may improve physical function, reduce inflammatory markers, and support healthier aging in animal models. Human research is still emerging, but the concept has generated significant interest in longevity medicine.
Senolytic therapies remain an active area of scientific investigation, and most are not yet approved specifically for anti-aging purposes. However, the growing understanding of cellular aging has opened a new frontier in preventive medicine. By addressing aging at the cellular level, senolytics may eventually become an important strategy for promoting healthspan—the number of years spent in good health—not just lifespan.
